February 6, 2024
Astellas CFO Atsushi Kitamura Astellas Pharma on February 5 cut its consolidated sales forecast for the fiscal year ending March 2024, accompanying the significant downturn in the outlook for its hot flash drug Veozah (fezolinetant). Veozah was launched in the...read more